Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.55 |
| ▸ | FLT1 | P17948 | 6/20 | 0.55 |
| ▸ | MET | P08581 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | ABL2 | P42684 | 2/20 | 0.55 |
| ▸ | FRK | P42685 | 2/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.55 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670821 | 0.93 | KDR (0.53) | KDRFLT1METFLT3FLT4 | |
| SCHEMBL2671112 | 0.92 | KDR (0.57) | KDRFLT1METFLT3FLT4 | |
| SCHEMBL1479037 | 0.86 | KDR (0.54) | KDRFLT1METFLT3FLT4 | |
| SCHEMBL2670885 | 0.84 | MET (0.73) | KDRMETFLT3KITABL1 | |
| SCHEMBL1478499 | 0.84 | KDR (0.54) | KDRFLT1METFLT3KIT | |
| SCHEMBL1478576 | 0.81 | FLT3 (0.68) | KDRMETFLT3KITABL1 | |
| SCHEMBL1479677 | 0.81 | FLT3 (0.68) | KDRMETFLT3KITABL1 | |
| SCHEMBL1481434 | 0.81 | FLT3 (0.68) | KDRMETFLT3KITABL1 | |
| SCHEMBL2536586 | 0.79 | MET (0.66) | KDRMETFLT3KITABL1 | |
| SCHEMBL2671428 | 0.79 | MET (0.51) | KDRMETFLT3KITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165477-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | KDR 11/4885FLT1 5/4885MET 3/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | KDR 11/4885FLT1 5/4885MET 3/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | KDR 11/4885FLT1 5/4885MET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.